BioMe™ Biobank Program
Channeling the power of genomics and BIG data to elevate medical decision-making and optimize the customization of healthcare.
For pharmaceutical and biotech companies, drug development is multifaceted. For doctors, the administration of medical care is complex. For patients, undergoing the right treatment is decisive.
The Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai is leading the radical movement toward diagnoses & classification of disease according to the patient’s molecular profile, accommodating differences at all possible levels of exposure (genome + environment + lifestyle) and at all stages of the process, from prevention to post-treatment follow-up. Personalized medicine is what drives our Institute's research. Help us answer the question being asked by the drug designer, the practitioner, and by YOU: “Is this therapy going to work for me?”
“Despite what you see in the media, DNA is not just for crime scene analysis and paternity suits! DNA is the key to unlocking the causes of disease and all of our own personal risks for future ailments. It can predict not only ours but our children’s potential problems in time to change the course of disease and history at the same time! Investing your money and your DNA in the Biobank is the best investment you can ever make in you and your family’s health.”
- Douglas T. Dieterich, MD; Professor of Medicine; Division of Liver Diseases; Icahn School of Medicine at Mount Sinai
“The World's Top 10 Most Innovative Companies in Big Data …Mount Sinai Icahn School of Medicine For embracing data scientists and supercomputers to build the hospital of the future. …At the heart of Mount Sinai’s efforts are...BioMe™ , a database of genomic samples from more than 25,000 patients.
-Fast Company, February 2014
“…A potentially revolutionary new tool…Mount Sinai leads in a new era of precision medicine…”
- U.S. News and World Report, Best Hospitals, 2013 Edition
“…one of the first hospitals to make patients' genomic sequence linkable to their electronic medical records for clinical use…”
- GenomeWeb, December 2011